Avalo Therapeutics (AVTX) Operating Income (2014 - 2026)
Avalo Therapeutics (AVTX) reported Operating Income of -$20.9 million for Q1 2026, down 42.48% on a YoY basis from -$36.3 million in Q1 2025, and down 5.87% quarter-over-quarter from -$19.7 million in Q4 2025.
Avalo Therapeutics (AVTX) Operating Income (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Operating Income for 13 years, with the latest figure at -$20.9 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 42.48% year-over-year to -$20.9 million; the trailing twelve-month figure through Mar 2026 stood at -$79.2 million (down 57.01% YoY), and the FY2025 full-year result was -$72.9 million, down 6.44% from the prior year.
- Operating Income for Q1 2026 stood at -$20.9 million, down from -$19.7 million in the prior quarter.
- The five-year high for Operating Income was $4.1 million in Q3 2022, with the low at -$32.8 million in Q1 2024.
- Historically, Operating Income has averaged -$13.4 million across 5 years, with a median of -$12.9 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Income soared 124.87% — and 2024, when it slumped 272.69%.
- Avalo Therapeutics' Operating Income stood at -$8.9 million in 2022, then advanced by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then tumbled by 48.31% to -$19.7 million in 2025, then decreased by 5.87% to -$20.9 million in 2026.
- The last three Operating Income figures came in at -$20.9 million (Q1 2026), -$19.7 million (Q4 2025), and -$19.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Avalo Therapeutics | 296.38 Mn | 296.38 Mn | - | -20.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.90 Mn |
| Dec 31, 2025 | -19.74 Mn |
| Sep 30, 2025 | -19.20 Mn |
| Jun 30, 2025 | -19.32 Mn |
| Mar 31, 2025 | -14.67 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -12.86 Mn |
| Jun 30, 2024 | -9.58 Mn |
| Mar 31, 2024 | -32.77 Mn |
| Dec 31, 2023 | -7.66 Mn |
| Sep 30, 2023 | -3.75 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -8.79 Mn |
| Dec 31, 2022 | -8.86 Mn |
| Sep 30, 2022 | 4.10 Mn |
| Jun 30, 2022 | -11.83 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -17.96 Mn |
| Sep 30, 2021 | -16.46 Mn |
| Jun 30, 2021 | -17.13 Mn |